IC‐03‐02: MODELING LONGITUDINAL FLORBETAPIR CHANGE ACROSS THE DISEASE SPECTRUM | Zendy

Landau Susan | Zendy; Fero Allison | Zendy; Baker Suzanne | Zendy; Jagust William | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

IC‐03‐02: MODELING LONGITUDINAL FLORBETAPIR CHANGE ACROSS THE DISEASE SPECTRUM

Author(s) -

Landau Susan,

Fero Allison,

Baker Suzanne,

Jagust William

Publication year - 2014

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2014.04.031

Subject(s) - alzheimer's disease neuroimaging initiative , standardized uptake value , longitudinal study , amyloid (mycology) , neuroimaging , medicine , disease , positron emission tomography , psychology , alzheimer's disease , pathology , nuclear medicine , neuroscience

SUVR images at 50-70 min after [11 C]Pittsburgh compound B injection in all patients and HCs.Results:All patients and HCswere PIB-negative except one PIB-positive patient with CBS and one HC. SPM analysis showed high [11 C] PBB3 binding in globus pallidus, putamen, thalamus, subthalamus, midbrain, pons, and peri-rolandic areas in PSP patients comparedwithHCs. PIB-negative CBS patients (n1⁄44) showed high [11 C]PBB3 binding in peri-rolandic areas, supplementary motor area, subthalamus, and midbrain compared with HCs. SUVR images of one PIB-positive patient with CBS showed high [11 C] PBB3 binding in the whole cerebral cortex including limbic cortex like advanced AD patients. Conclusions: The distribution of [11 C]PBB3 binding in the patients was in accord with the known distribution of tau pathology in PSP and CBD. The present study supports the utility of [11 C]PBB3-PET for detecting tau deposition in non-AD tauopathies including PSP and CBD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research